American Capital Management Inc. Purchases Shares of 235,152 DexCom, Inc. $DXCM

Key Points

• American Capital Management acquired 235,152 DexCom shares worth approximately $15.8 million, representing about 0.06% of the company. Institutional investors and hedge funds collectively own 97.75% of DXCM.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $88.71; several firms recently raised their targets, while Bank of America lowered its target to $80 but retained a Buy rating.
• DexCom reported quarterly EPS of $0.70, beating estimates by $0.09, while revenue rose 13.1% year over year to $1.31 billion. Company insiders have sold 73,035 shares worth roughly $5.45 million over the past 90 days.

American Capital Management Inc. bought a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 235,152 shares of the medical device company's stock, valued at approximately $15,837,000. American Capital Management Inc. owned approximately 0.06% of DexCom at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in DXCM. Brighton Jones LLC lifted its holdings in shares of DexCom by 257.7% during the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company's stock worth $1,290,000 after purchasing an additional 11,946 shares during the period. Integrated Wealth Concepts LLC increased its stake in DexCom by 6.3% in the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company's stock valued at $227,000 after buying an additional 196 shares during the period. Empowered Funds LLC raised its position in DexCom by 5.4% during the 1st quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company's stock worth $577,000 after buying an additional 436 shares during the last quarter. Focus Partners Wealth raised its position in DexCom by 13.2% during the 1st quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company's stock worth $493,000 after buying an additional 841 shares during the last quarter. Finally, NewEdge Advisors LLC lifted its stake in shares of DexCom by 1.4% in the 2nd quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company's stock worth $1,681,000 after acquiring an additional 258 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.55, for a total transaction of $128,435.00. Following the completion of the transaction, the executive vice president directly owned 106,353 shares in the company, valued at approximately $8,034,969.15. This represents a 1.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,912 shares of the firm's stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $73.00, for a total transaction of $358,576.00. Following the transaction, the executive vice president directly owned 100,361 shares of the company's stock, valued at approximately $7,326,353. This represents a 4.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 73,035 shares of company stock worth $5,446,673. 0.28% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on DXCM. Weiss Ratings raised shares of DexCom from a "hold (c-)" rating to a "hold (c)" rating in a research note on Tuesday, August 11th. Bank of America decreased their price objective on shares of DexCom from $100.00 to $80.00 and set a "buy" rating on the stock in a report on Monday, May 18th. Royal Bank Of Canada upped their target price on shares of DexCom from $85.00 to $90.00 and gave the stock an "outperform" rating in a research report on Friday, July 31st. Benchmark increased their target price on shares of DexCom from $77.00 to $82.00 and gave the company a "buy" rating in a report on Friday, July 31st. Finally, TD Cowen reiterated a "buy" rating on shares of DexCom in a research report on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $88.71.

DexCom Trading Down 0.2%

DXCM stock opened at $88.96 on Thursday. The company has a market cap of $33.57 billion, a price-to-earnings ratio of 35.16, a PEG ratio of 1.50 and a beta of 1.41. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. The business has a fifty day simple moving average of $78.50 and a 200-day simple moving average of $71.33. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $92.59.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The company had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. During the same period in the previous year, the firm earned $0.48 earnings per share. DexCom's revenue for the quarter was up 13.1% on a year-over-year basis. On average, equities research analysts expect that DexCom, Inc. will post 2.64 EPS for the current year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source